Wall Street is missing the forest for the trees, and the opportunity is enormous. The injectable weight loss drugs known as GLP-1 agonists have taken the world by storm. And the stocks of the companies making the drugs have crushed the market over the past couple of years. However, an industrywide shortage for the drugs opened the door for companies like Hims & Hers Health (HIMS -0.83%) to compete by offering lower-priced compounded versions mixed up by their teams. Hims & Hers stocks took flight once the c ...